Resources

Select from the drop-down menu below to read the most up-to-date news about pelareorep.

October 23, 2023 | Poster
Pelareorep (pela) + atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients – Results from the GOBLET study
Arnold, Dirk et al. Previously presented at ESMO Congress 2023, Oct. 23, 2023
October 23, 2023 | Poster
Pelareorep + atezolizumab and chemotherapy in third-line (3L) metastatic colorectal cancer (mCRC) patients – Interim results from the GOBLET study
Ungerechts, Guy et al. Previously presented at ESMO Congress 2023, Oct. 22, 2023
November 10, 2022 | Media Coverage
Oncolytics Presents Promising Pancreatic Cancer Data at SITC
November 8, 2022 | Poster
Pelareorep combined with atezolizumab and chemotherapy demonstrates encouraging results as first-line treatment in advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients – Interim results from the GOBLET study
Arnold, Dirk et al, Previously presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting; November 8-12, 2022
June 29, 2022 | Poster
GOBLET: A phase 1/2 multiple indication signal finding and biomarker study in advanced gastrointestinal cancers treated with pelareorepand atezolizumab –safety and preliminary response results
Collienne, Maike et al, Previously presented at the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022; June 29 – July 2, 2022
January 20, 2022 | Poster
GOBLET: A phase 1 / 2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic gastrointestinal cancers exploring treatment combinations with pelareorep and atezolizumab
Arnold, Dirk et al, Previously presented at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 20-22, 2022

Expanded Access

Oncolytics believes that participating in clinical trials is the best way for patients to access pelareorep. We are not currently able to fulfill expanded access requests at this time.

Information on many of Oncolytics clinical trials can be found at Home – ClinicalTrials.gov. If a treating physician would like additional information, the physician should directly contact Oncolytics at info@oncolytics.ca.

Information on many of Oncolytics clinical trials can be found at Home – ClinicalTrials.gov. If a treating doctor would like additional information, the doctor should formally contact Oncolytics at info@oncolytics.ca.

Contact Us

For questions regarding our science, partnership opportunities, or other inquiries, we encourage you to reach out.

Get in touch